Newsletter

Hogs Growth Momentum!!

Tianli Agritech, Inc. (OINK)

Keep a close eye on OINK. The company delivered another solid quarter on its financial results.

For the first quarter 2014, OINK posted revenue of $9.72 million, an approximately 32% increase year over year, gross profit of $1.46 million, compared to $0.81 million for the same period the prior year, and net income of $0.30 million, compared to a net loss of $0.18 million in the first quarter 2013.

As of March 31, 2014, OINK had cash and cash equivalents of $19.53 million, compared to $10.09 million at the end of 2013.

OINK is in the business of breeding, raising and selling breeder and market hogs in China and is developing a retail channel for its pork products including high-value, black hog meat.

More about Tianli Agritech, Inc. (OINK) at www.tianli-china.com

**

IsoRay, Inc. (ISR)

Part of the central nervous system, the brain is the control center for vital functions of the body, including speech, movement, thoughts, feelings, memory, vision, hearing and more. A brain tumor is an abnormal growth of tissue in the brain or central spine that can disrupt proper brain function.

Metastatic brain tumors are called secondary brain tumors as they are caused by cancer cells spreading (metastasizing) from another area of the body through the bloodstream to the brain. Metastatic brain tumors are five times more common than primary brain tumors. The most common types of cancer that cause metastatic brain tumors are lung cancer, breast cancer, melanoma (skin cancer), colon cancer, kidney (renal) cancer, and thyroid cancer. Metastatic brain tumors are always malignant (cancerous).

Glioblastoma is a fast-growing, central nervous system tumor that forms from supportive tissue of the brain and spinal cord. Glioblastoma usually occurs in adults and affects the brain more often than the spinal cord.

ISR reported that it has received final approval from the State of Washington Department of Health to manufacture its recently FDA cleared Liquid Cesium-131 (Cesitrex(R)) for use with GliaSite(R) balloon catheter for the treatment of metastatic and glioblastoma brain cancers.

The GliaSite(R) balloon catheter can now incorporate the use of Liquid Cesium-131 for the treatment of metastatic and glioblastoma brain cancers and ISR's management believes this combination will offer a number of advantages in treating these debilitating brain cancers.

Liquid Cesium-131 eliminates the need for a thyroid block as required with Iodine-125, is safer for the patient and staff, and if a spill were to occur, it is an easier cleanup than with other isotopes.

A specified dose of Liquid Cesium-131 within the balloon is placed in the tumor cavity most likely to contain cancer cells following surgery. This form of radiation is less likely to damage healthy brain tissue than other available alternatives. The ability for the tumor to recur is greatly diminished by treating the tumor bed immediately at the time of surgery with a single treatment, impacting patient longevity and quality of life.

ISR is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

More about IsoRay, Inc. (ISR) at www.isoray.com.

**

General Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Statements on this website or newsletter may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained on this website. The Company disclaims any obligation to update any statements in this website. These stock quotes and related data are provided for information purposes only and are not intended for trading purposes. Crown Equity Holdings Inc. will not be liable for any inaccuracies or delays in such data, or for any actions taken in reliance thereon. Potential investors should seek independent information and advice from qualified investment professionals prior to investment. Crown Equity Holdings Inc. provides links to websites operated by third parties. These links may be of interest or of use to you, and are provided for convenience only. You should be aware that in using these links, you are leaving Crown Equity Holdings Inc’s website. Crown Equity Holdings Inc. does not approve or endorse the content, information or materials available on such third party websites. In addition, Crown Equity Holdings Inc. makes no representation regarding, and is not responsible for, the content, information or material available on such websites. If you decide to access such websites or newsletter you do this at your own risk, and Crown Equity Holdings Inc. will not be liable for any loss or damage associated with your use of, or reliance on, the content, information or material available on such website.